Global Neurodegenerative Diseases Drug Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Immunomodulator
  • 1.4.3 Interferons
  • 1.4.4 Decarboxylase Inhibitors
  • 1.4.5 Dopamine Agonists
  • 1.4.6 Others
• 1.5 Market by Application
  • 1.5.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2020 VS 2026
  • 1.5.2 Multiple Sclerosis
  • 1.5.3 Parkinson’s Disease
  • 1.5.4 Alzheimer’s Disease
  • 1.5.5 Spinal Muscular Atrophy (SMA)
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Neurodegenerative Diseases Drug Market Perspective (2015-2026)
• 2.2 Neurodegenerative Diseases Drug Growth Trends by Regions
  • 2.2.1 Neurodegenerative Diseases Drug Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neurodegenerative Diseases Drug Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Neurodegenerative Diseases Drug Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Neurodegenerative Diseases Drug Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Neurodegenerative Diseases Drug Players by Market Size
  • 3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2015-2020)
  • 3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Neurodegenerative Diseases Drug Market Concentration Ratio
  • 3.2.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2019
• 3.3 Neurodegenerative Diseases Drug Key Players Head office and Area Served
• 3.4 Key Players Neurodegenerative Diseases Drug Product Solution and Service
• 3.5 Date of Enter into Neurodegenerative Diseases Drug Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2015-2020)
• 4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2021-2026)

5 Neurodegenerative Diseases Drug Breakdown Data by Application (2015-2026)

• 5.1 Global Neurodegenerative Diseases Drug Market Size by Application (2015-2020)
• 5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neurodegenerative Diseases Drug Market Size (2015-2020)
• 6.2 Neurodegenerative Diseases Drug Key Players in North America (2019-2020)
• 6.3 North America Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 6.4 North America Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Neurodegenerative Diseases Drug Market Size (2015-2020)
• 7.2 Neurodegenerative Diseases Drug Key Players in Europe (2019-2020)
• 7.3 Europe Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 7.4 Europe Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

8 China

• 8.1 China Neurodegenerative Diseases Drug Market Size (2015-2020)
• 8.2 Neurodegenerative Diseases Drug Key Players in China (2019-2020)
• 8.3 China Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 8.4 China Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Neurodegenerative Diseases Drug Market Size (2015-2020)
• 9.2 Neurodegenerative Diseases Drug Key Players in Japan (2019-2020)
• 9.3 Japan Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 9.4 Japan Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Neurodegenerative Diseases Drug Market Size (2015-2020)
• 10.2 Neurodegenerative Diseases Drug Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 10.4 Southeast Asia Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

11 India

• 11.1 India Neurodegenerative Diseases Drug Market Size (2015-2020)
• 11.2 Neurodegenerative Diseases Drug Key Players in India (2019-2020)
• 11.3 India Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 11.4 India Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Neurodegenerative Diseases Drug Market Size (2015-2020)
• 12.2 Neurodegenerative Diseases Drug Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
• 12.4 Central & South America Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Biogen
  • 13.1.1 Biogen Company Details
  • 13.1.2 Biogen Business Overview and Its Total Revenue
  • 13.1.3 Biogen Neurodegenerative Diseases Drug Introduction
  • 13.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2015-2020))
  • 13.1.5 Biogen Recent Development
• 13.2 Pfizer
  • 13.2.1 Pfizer Company Details
  • 13.2.2 Pfizer Business Overview and Its Total Revenue
  • 13.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
  • 13.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.2.5 Pfizer Recent Development
• 13.3 Roche
  • 13.3.1 Roche Company Details
  • 13.3.2 Roche Business Overview and Its Total Revenue
  • 13.3.3 Roche Neurodegenerative Diseases Drug Introduction
  • 13.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.3.5 Roche Recent Development
• 13.4 Novartis
  • 13.4.1 Novartis Company Details
  • 13.4.2 Novartis Business Overview and Its Total Revenue
  • 13.4.3 Novartis Neurodegenerative Diseases Drug Introduction
  • 13.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.4.5 Novartis Recent Development
• 13.5 Sanofi
  • 13.5.1 Sanofi Company Details
  • 13.5.2 Sanofi Business Overview and Its Total Revenue
  • 13.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
  • 13.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.5.5 Sanofi Recent Development
• 13.6 Teva Pharmaceuticals
  • 13.6.1 Teva Pharmaceuticals Company Details
  • 13.6.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
  • 13.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
  • 13.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.6.5 Teva Pharmaceuticals Recent Development
• 13.7 Orion Pharma Ltd
  • 13.7.1 Orion Pharma Ltd Company Details
  • 13.7.2 Orion Pharma Ltd Business Overview and Its Total Revenue
  • 13.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
  • 13.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.7.5 Orion Pharma Ltd Recent Development
• 13.8 UCB S.A
  • 13.8.1 UCB S.A Company Details
  • 13.8.2 UCB S.A Business Overview and Its Total Revenue
  • 13.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
  • 13.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.8.5 UCB S.A Recent Development
• 13.9 ACADIA Pharmaceuticals Inc.
  • 13.9.1 ACADIA Pharmaceuticals Inc. Company Details
  • 13.9.2 ACADIA Pharmaceuticals Inc. Business Overview and Its Total Revenue
  • 13.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
  • 13.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.9.5 ACADIA Pharmaceuticals Inc. Recent Development
• 13.10 Lundbeck Pharmaceuticals Italy S.p.A.
  • 13.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
  • 13.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview and Its Total Revenue
  • 13.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
  • 13.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 13.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
• 13.11 Mitsubishi Tanabe Pharma America
  • 10.11.1 Mitsubishi Tanabe Pharma America Company Details
  • 10.11.2 Mitsubishi Tanabe Pharma America Business Overview and Its Total Revenue
  • 10.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
  • 10.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
  • 10.11.5 Mitsubishi Tanabe Pharma America Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer